Navigation Links
CDC Issues Guidance on Daily Pill to Prevent Infection With HIV

By Amanda Gardner
HealthDay Reporter

THURSDAY, Jan. 27 (HealthDay News) -- U.S. health authorities on Thursday issued an "interim guidance" to help doctors and patients using Truvada, the once-a-day combination pill that was shown in November to help prevent the spread of HIV in high-risk individuals.

The guidance, from experts at the U.S. Centers for Disease Control and Prevention, stresses that only gay and bisexual men at high risk for contracting the virus -- the same population included in the study -- should use the pill.

When used as a preventive agent, the medication should only be given to men who are currently HIV-negative and only as part of a larger prevention plan that includes testing for other sexually transmitted diseases, counseling and using condoms faithfully.

"While we think this is really a very important new tool in HIV prevention, it has only been proven safe and effective with men who have sex with men, so at this point we don't feel we have the information to discuss its use for anyone other than [this group]," said Dr. Dawn Smith, lead author of the new guidance, which appears in the Jan. 28 issue of the CDC journal Morbidity and Mortality Weekly Report.

Even for highly sexually active gay and bisexual men, "it's not the first line of prevention," Smith said. "It's meant for men who are unable to successfully, consistently use standard methods of reducing their risk of acquiring HIV."

In essence, Truvada is "meant to function as a safety net in addition to those methods. So if a man can't use condoms consistently then maybe [Truvada] would be helpful while they improve condom use," Smith said.

Truvada is a combination of two anti-HIV drugs, emtricitabine (Emtriva) and tenofovir (Viread), included in a once-a-day pill. The pill is already available by prescription as a treatment for HIV infection.

A study published Nov. 25 in the New England Journal of Medicine found that it cut the risk of HIV infection by almost 44 percent in those at highest risk for contracting the virus, namely sexually active gay and bisexual men.

The risk reduction climbed to nearly 73 percent among study participants who took the pill 90 percent of the time, the researchers added.

Both the treatment and the control group in the study also received intensive counseling on safe sex practices and were given condoms (about 500,000 condoms were distributed throughout the course of the trial).

Men in the study reported having had an average of 18 sexual partners in the previous 12 weeks.

Another expert agreed, however, that Truvada is not meant to supplant the condom.

"There has always been a concern that people will see this as an either/or proposition [pill or condom] but it's clearly 'and,'" said Dr. Michael Horberg, director of HIV/AIDS at Kaiser Permanente Health Plan.

"A lot of organizations such as ours have strategized how best to interpret the study results and we totally agree with the considerations of the CDC," he said.

At the time the study was released, the CDC issued "immediate cautions" with similar but less specific recommendations.

This interim report includes more specific information, including getting tested and receiving safe-sex counseling every two to three months while on the medication.

The guidance is intended to fill a gap until formal U.S. Public Health Service guidelines are issued hopefully later this year, Smith said.

"We're working on the first draft of the formal guidelines but, because they involve other Health & Human Services agencies and a public comment process, we don't expect them until later this year," said Smith, who is a biomedical intervention implementation officer at the U.S. National Center for HIV/AIDS Prevention, part of the CDC.

One cloud in the silver lining: A year's worth of Truvada totals more than $10,000 a year, and that is the discounted rate. Generic versions are available in some countries (not the United States) for as low as $500 a year.

More information

There's more on HIV/AIDS at the CDC.

SOURCES: Dawn Smith, M.D., biomedical intervention implementation officer, National Center for HIV/AIDS Prevention, CDC; Michael Horberg, M.D., director, HIV/AIDS, Kaiser Permanente Health Plan; Jan. 28, 2011, Morbidity and Mortality Weekly Report

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Majority of Americans Approve of President Obamas Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television
2. American Red Cross Issues One-Month Progress Report for Haiti Earthquake
3. New study suggests stem cells sabotage their own DNA to produce new tissues
4. One in Two Children Has Chronic Health Issues
5. The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance
6. FDA Issues Warning on Key Asthma Drugs
7. Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles
8. CHIME Issues Comments on EHR Incentive Program
9. Americans Weigh in on Skincare Issues
10. Illinois State Senator Cullerton Recognized for Advocacy Work on Mental Health Issues
11. ATS issues statement on disorder of respiratory and autonomic nervous system regulation
Post Your Comments:
Related Image:
CDC Issues Guidance on Daily Pill to Prevent Infection With HIV
(Date:11/30/2015)... ... , ... According to an article published November 13th by People ... to show her Instagram followers that the praise that they were bestowing on her ... she didn’t “want to mislead any mommy's who just had babies and are stressing,” ...
(Date:11/30/2015)... ... ... A record crowd gathered at the Pennsylvania Biotech Center of Bucks County ... Institute. , The institute, which is the research arm of the Hepatitis B Foundation, ... conference, which focused on ways companies can work to reduce the cost and improve ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their ... setting. , When you have dental problems, you need to turn to a dentist ... diagnose and treat your needs, a friendly dentist who counsels you on the best ...
(Date:11/30/2015)... ... , ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, ... Medicine in 1935. His father graduated from NYU School of Dentistry in 1965. ... as their commitment and passion to the Practice of Dentistry. Continuing the family ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic pain, ... at the U.S. Patent and Trademark Office (USPTO) has denied ... Patent No. 8,359,102 (the ,102 patent).  ... unit of Boston Scientific Corporation filed two petitions challenging the ...
(Date:11/30/2015)... , Nov. 30, 2015 ... the "Orphan Drugs Market 2015-2019" report ... has announced the addition of the "Orphan ... --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to their ...
(Date:11/30/2015)... global cell culture market is expected ... bn by 2022 at a CAGR of 7.1% therein. --> ... its 2013 value of US$6.1 bn to US$11.3 bn by 2022 ... Research has announced the release of a new market research study, ... ,Cell Culture Market - Global Industry Analysis, Size, Share, Growth, Trends ...
Breaking Medicine Technology: